GLP-1 receptor agonists significantly cut postoperative surgical complications after dermatologic surgery

Patients undergoing dermatologic surgery, particularly for skin cancer, face risks of postoperative inflammatory complications such as infection, hematoma, and wound disruption. Current standard-of-care focuses on sterile technique and prophylactic antibiotics, but these complications remain a concern, impacting patient recovery and healthcare costs. Glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated anti-inflammatory and wound-healing properties in preclinical models, suggesting a potential beneficial role in surgical recovery beyond their metabolic effects. However, their specific impact on outcomes after dermatologic surgery has remained largely unexamined.

This retrospective cohort study used the TriNetX Research Network to identify patients undergoing Mohs Micrographic Surgery or wide local excisions for skin cancer. The intervention group took a GLP-1 receptor agonist (e.g., semaglutide, tirzepatide, liraglutide), while controls did not. Researchers assessed the one-month risk of postoperative inflammatory complications (IC), including wound disruption, hematoma, and infections. Hazard ratios and 95% confidence intervals were calculated after adjusting for demographics and comorbidities.